The technology behind our CalRexin™ calcitonin receptor antibody
Our Technology
Our technology is based on the only available monoclonal antibody against a definable and extracellular linear target of the human calcitonin receptor (CTR). Accumulation of the CTR on the cell surface is an event associated with cell stress and Programmed Cell Death (PCD) – this is one of our key discoveries. The extracellular target epitope of our antibody makes it a suitable target for the delivery of therapeutic or diagnostic substances to reach diseased cells and tissues.
Our unique antibody enables the development of novel conjugates with applications in research and imaging, diagnostics and therapeutic interventions.
Patents
PCT/AU2008/001435; WO 2009/039584, Patent No 2203747. Diagnosis and treatment of diseased and damaged tissue.
Int PCT/AU2014/001081 Marker of cell death.
Our pipeline is what sets us apart
CalRexin™ Research Reagents
Apop Biosciences is creating proprietary research reagents to help research scientists to be innovative in fields that involve Programmed Cell Death.
Image from confocal microscopy using CalRexin™:568
Cancer cells are treated with cytotoxin.
Green cells have tubulin and are intact, living cells that exclude CalRexin™:568
Red cells are dying, tubulin is lost and CalRexin™:568 accumulates.
CalRexin™ Therapeutics
CalRexin™:ADC (Antibody-Drug Conjugates) The potential to turn our product into a powerful delivery vehicle for new or established drugs in the treatment of recalcitrant diseases in patients. These ADCs have been recognised to have potential in the treatment of patients with a substantially lower risk of off target side effects.
ADCs allow for the targeted delivery of a potent chemotherapeutic or cancer cell toxin directly to the cancer cell and importantly, the cancer stem cell.
The specificity of the antibody determines the cancer indication that can be treated and for CalRexin™:ADC our initial focus will be brain cancer (glioblastoma) with potential application to brain and bone metastasis, prostate cancer and blood cancers.
CalRexin™ Imaging & Diagnostic Agents
CalRexin™:PET (Positron Emission Tomography) The potential for whole-body imaging of patients to identify programmed cell death, rather than having to remove cells from the body (biopsy), improves quality of life of cancer patients following radio- and chemotherapy treatment. CalRexin™:PET is also being developed as a diagnostic for Multiple Organ Dysfunction Syndrome (MODS) in patients with a high viral load (COVID, HIV).
